The pharmacological effects of cicaprost, an oral prostacyclin analogue, in patients with Raynaud's syndrome secondary to systemic sclerosis: a preliminary study

C S Lau, M McLaren, A Saniabadi, N Scott, J J Belch

    Research output: Contribution to journalArticle

    12 Citations (Scopus)

    Abstract

    Prostacyclin (PGI2) and its analogues are useful treatments for patients with secondary Raynaud's syndrome (RS). However, they have to be given intravenously, causing inconvenience to patients. Cicaprost is an orally available analogue of PGI2 and has been shown to inhibit platelet aggregation in both in vitro and animal studies. We recently investigated the effects of cicaprost on whole blood platelet aggregation, red cell deformability, white cell function (polymorphonuclear cell aggregation, elastase release and free radical activity) and plasma fibrinolysis in 14 patients with systemic sclerosis (SSc) and secondary RS. Patients received cicaprost (2.5 micrograms or 5 micrograms t.i.d.) or matching placebo tablets orally for 10 days. Blood samples were taken at baseline and 2 hours after administration of the last treatment for the above mentioned assays. No changes were observed in any of the cellular elements and parameters measured in the 3 groups of patients studied. Our study suggests that cicaprost, at doses up to 5 micrograms t.i.d., fails to modify the blood coagulation elements and factors in patients with RS secondary to SSc. Further studies using higher doses and longer study periods are planned.
    Original languageEnglish
    Pages (from-to)271-273
    Number of pages3
    JournalClinical and Experimental Rheumatology
    Volume9
    Issue number3
    Publication statusPublished - 1991

    Fingerprint

    Systemic Scleroderma
    Epoprostenol
    Pharmacology
    Platelet Aggregation
    Cell Aggregation
    Blood Coagulation Factors
    Pancreatic Elastase
    Fibrinolysis
    Tablets
    Free Radicals
    cicaprost
    Blood Platelets
    Placebos
    Therapeutics

    Cite this

    @article{73a3e73c2e4e49aeac3c4830d76b2d2a,
    title = "The pharmacological effects of cicaprost, an oral prostacyclin analogue, in patients with Raynaud's syndrome secondary to systemic sclerosis: a preliminary study",
    abstract = "Prostacyclin (PGI2) and its analogues are useful treatments for patients with secondary Raynaud's syndrome (RS). However, they have to be given intravenously, causing inconvenience to patients. Cicaprost is an orally available analogue of PGI2 and has been shown to inhibit platelet aggregation in both in vitro and animal studies. We recently investigated the effects of cicaprost on whole blood platelet aggregation, red cell deformability, white cell function (polymorphonuclear cell aggregation, elastase release and free radical activity) and plasma fibrinolysis in 14 patients with systemic sclerosis (SSc) and secondary RS. Patients received cicaprost (2.5 micrograms or 5 micrograms t.i.d.) or matching placebo tablets orally for 10 days. Blood samples were taken at baseline and 2 hours after administration of the last treatment for the above mentioned assays. No changes were observed in any of the cellular elements and parameters measured in the 3 groups of patients studied. Our study suggests that cicaprost, at doses up to 5 micrograms t.i.d., fails to modify the blood coagulation elements and factors in patients with RS secondary to SSc. Further studies using higher doses and longer study periods are planned.",
    author = "Lau, {C S} and M McLaren and A Saniabadi and N Scott and Belch, {J J}",
    year = "1991",
    language = "English",
    volume = "9",
    pages = "271--273",
    journal = "Clinical and Experimental Rheumatology",
    issn = "0392-856X",
    publisher = "Clinical and Experimental Rheumatology S.A.S.",
    number = "3",

    }

    TY - JOUR

    T1 - The pharmacological effects of cicaprost, an oral prostacyclin analogue, in patients with Raynaud's syndrome secondary to systemic sclerosis

    T2 - a preliminary study

    AU - Lau, C S

    AU - McLaren, M

    AU - Saniabadi, A

    AU - Scott, N

    AU - Belch, J J

    PY - 1991

    Y1 - 1991

    N2 - Prostacyclin (PGI2) and its analogues are useful treatments for patients with secondary Raynaud's syndrome (RS). However, they have to be given intravenously, causing inconvenience to patients. Cicaprost is an orally available analogue of PGI2 and has been shown to inhibit platelet aggregation in both in vitro and animal studies. We recently investigated the effects of cicaprost on whole blood platelet aggregation, red cell deformability, white cell function (polymorphonuclear cell aggregation, elastase release and free radical activity) and plasma fibrinolysis in 14 patients with systemic sclerosis (SSc) and secondary RS. Patients received cicaprost (2.5 micrograms or 5 micrograms t.i.d.) or matching placebo tablets orally for 10 days. Blood samples were taken at baseline and 2 hours after administration of the last treatment for the above mentioned assays. No changes were observed in any of the cellular elements and parameters measured in the 3 groups of patients studied. Our study suggests that cicaprost, at doses up to 5 micrograms t.i.d., fails to modify the blood coagulation elements and factors in patients with RS secondary to SSc. Further studies using higher doses and longer study periods are planned.

    AB - Prostacyclin (PGI2) and its analogues are useful treatments for patients with secondary Raynaud's syndrome (RS). However, they have to be given intravenously, causing inconvenience to patients. Cicaprost is an orally available analogue of PGI2 and has been shown to inhibit platelet aggregation in both in vitro and animal studies. We recently investigated the effects of cicaprost on whole blood platelet aggregation, red cell deformability, white cell function (polymorphonuclear cell aggregation, elastase release and free radical activity) and plasma fibrinolysis in 14 patients with systemic sclerosis (SSc) and secondary RS. Patients received cicaprost (2.5 micrograms or 5 micrograms t.i.d.) or matching placebo tablets orally for 10 days. Blood samples were taken at baseline and 2 hours after administration of the last treatment for the above mentioned assays. No changes were observed in any of the cellular elements and parameters measured in the 3 groups of patients studied. Our study suggests that cicaprost, at doses up to 5 micrograms t.i.d., fails to modify the blood coagulation elements and factors in patients with RS secondary to SSc. Further studies using higher doses and longer study periods are planned.

    M3 - Article

    C2 - 1879086

    VL - 9

    SP - 271

    EP - 273

    JO - Clinical and Experimental Rheumatology

    JF - Clinical and Experimental Rheumatology

    SN - 0392-856X

    IS - 3

    ER -